HomeAI · summaries
Storia in 11 fonti
Samsung Bio to expand its wheelhouse in $1.8B buy for peptide API maker
Samsung Biologics offers $1.8B for Swiss CDMO PolyPeptide, expanding beyond biologics into peptide APIs and the booming GLP-1 manufacturing market.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
asiabusinessoutlook.com
1.8B Deal Puts Samsung Biologics Ahead in CDMO Race
Samsung Biologics proposed acquisition marks a decisive move to consolidate its position as a global contract development and manufacturing organization
- ·
swissinfo.ch
Samsung Biologics to Buy PolyPeptide in $1.8 Billion Deal
(Bloomberg) -- Samsung Biologics Co. agreed to acquire Switzerland’s PolyPeptide Group AG in an all-cash deal that values the contract drugmaker’s equity at about 1.46 billion…
